This publication describes the methodologies used by the Drug Abuse Warning Network (DAWN), to collect, prepare, and analyze information on drug-related emergency department (ED) visits in the United States. The methods described here were initiated in 2004 and are current as of 2011.

This Drug Abuse Warning Network (DAWN) short report summarizes key findings about drug-related emergency department visits between 2004 and 2010. The report includes data for illicit drugs, alcohol, and prescription and over-the counter medications. For medications, the report looks at misuse and abuse, adverse reactions, and accidental ingestion of drugs by children.

Preliminary Findings from Drug-Related Emergency Department Visits, 2021. An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP22-07-03-001.pdf

,The Drug Abuse Warning Network (DAWN) survey is designed to capture data on emergency department (ED) episodes that are induced by or related to the use of an illicit, prescription, or over-the-counter drug. For purposes of this collection, a drug "episode" is an ED visit that was induced by or related to the use of an illegal drug or the nonmedical use of a legal drug for patients aged six years and older. A drug "mention" refers to a substance that was mentioned during a drug-related ED episode. Because up to four drugs can be reported for each drug abuse episode, there are more mentions than episodes in the data. Individual persons may also be included more than once in the data. Within each facility participating in DAWN, a designated reporter, usually a member of the emergency department or medical records staff, was responsible for identifying drug-related episodes and recording and submitting data on each case. An episode report was submitted for each patient visiting a DAWN emergency department whose presenting problem(s) was/were related to their own drug use. DAWN produces estimates of drug-related emergency department visits for 50 specific drugs, drug categories, or combinations of drugs, including the following: acetaminophen, alcohol in combination with other drugs, alprazolam, amitriptyline, amphetamines, aspirin, cocaine, codeine, diazepam, diphenhydramine, fluoxetine, heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam, marijuana/hashish, methadone, methamphetamine, and PCP/PCP in combination with other drugs. The use of alcohol alone is not reported. The route of administration and form of drug used (e.g., powder, tablet, liquid) are included for each drug. Data collected for DAWN also include drug use motive and total drug mentions in the episode, as well as race, age, patient disposition, reason for ED visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.,

Data tables consisting of Excel files with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for drug-related emergency department visits for the Nation and 11 metropolitan areas/divisions. Tables are provided for 10 topics (\"analytic categories\") which are defined in the \"Guide to Drug Abuse Warning Trend Tabls,\" a separate document. Each table includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology. Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.

,The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year. DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit. The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.,

Use this summary report to properly interpret 2021 NSDUH estimates of substance use and mental health issues. The report accompanies theannual detailed tablesand covers overall methodology, key definitions for measures and terms used in 2021 NSDUH reports and tables, and selected analyses of the measures and how they should be interpreted.The report is organized into six chapters:Introduction.Description of the survey, including information about the sample design, data collection procedures, and key aspects of data processing such as development of the analysis weights. The report also includes methodological changes and related issues in the 2021 NSDUH due to COVID-19.Technical details on the statistical methods and measurement, such as suppression criteria for unreliable estimates, statistical testing procedures, issues around selected substance use and mental health measures, and the impact of methodological changes on response rates.Special topics related to prescription psychotherapeutic drugs.A comparison between NSDUH and other sources of data on substance use and mental health issues, including data sources for populations outside the NSDUH target population.A more in-depth view of special methodological issues for the 2021 NSDUH, including the results of special analyses that led SAMHSA to not compare estimates from 2021 to estimates from previous years.An appendix covers key definitions used in NSDUH reports and tables.

,The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year. DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit. The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.,

Drug Abuse Warning Network (DAWN) Non-Fatal Overdoses Short Report presents: (1) national estimates and characteristics of non-fatal overdose ED visits, (2) the identification of top substances involved in these visits and (3) the prevalence of polysubstance related non-fatal overdose ED visits. Additional report resources are also available in theNon-Fatal Overdoses Short Report - Companion Document.

This Drug Abuse Warning Network (DAWN) spotlight is about emergency department visits involving nonmedical use of phamaceuticals by gender among older adolescents age 12 to 17 from year 2010.